Go Pro
→ This looks like plywood. It's not. (From Eagle Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$3.47
-0.3%		$2.95
$1.56
▼
$4.23
$588.32M3.274.73 million shs4.86 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%		$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
ProKidney Corp. stock logo
PROK
ProKidney
$2.01
+4.7%		$1.68
$1.30
▼
$3.48
$607.67M1.71.22 million shs1.22 million shs
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%+11.22%+25.72%+6.77%+121.02%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+316.62%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%+9.84%+22.56%+11.67%-14.83%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$3.47
-0.3%		$2.95
$1.56
▼
$4.23
$588.32M3.274.73 million shs4.86 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%		$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
ProKidney Corp. stock logo
PROK
ProKidney
$2.01
+4.7%		$1.68
$1.30
▼
$3.48
$607.67M1.71.22 million shs1.22 million shs
VectivBio Holding AG stock logo
VECT
VectivBio
$16.85
$16.85
$4.25
▼
$16.98
N/AN/AN/AN/A
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%+11.22%+25.72%+6.77%+121.02%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+316.62%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%+9.84%+22.56%+11.67%-14.83%
VectivBio Holding AG stock logo
VECT
VectivBio
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
2.75
Moderate Buy$15.33341.88% Upside
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1.88
Reduce$30.755.74% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00497.01% Upside
VectivBio Holding AG stock logo
VECT
VectivBio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MRSN, VECT, CABA, and PROK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$16.00
8/24/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/14/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$4.00 ➝ $3.00
7/17/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
ProKidney Corp. stock logo
PROK
ProKidney
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/25/2026
ProKidney Corp. stock logo
PROK
ProKidney
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$1.24 per shareN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$33.18M4.38N/AN/A($1.92) per share-15.15
ProKidney Corp. stock logo
PROK
ProKidney
$818K742.87N/AN/A($2.92) per share-0.69
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$167.86M-$1.57N/AN/AN/AN/A-128.27%-95.47%11/9/2026 (Estimated)
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/A
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest MRSN, VECT, CABA, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.3729-$0.34+$0.0329-$0.34$1.67 millionN/A
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
5.79
5.79
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.39
1.39
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36
VectivBio Holding AG stock logo
VECT
VectivBio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
VectivBio Holding AG stock logo
VECT
VectivBio
N/A

Insider Ownership

CompanyInsider Ownership
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
6.44%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
13.00%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
VectivBio Holding AG stock logo
VECT
VectivBio
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
50169.54 million158.63 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1505.00 million4.35 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3302.32 million181.91 millionOptionable
VectivBio Holding AG stock logo
VECT
VectivBio
30N/AN/ANo Data

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln
July 12, 2026  |  nasdaq.comhttps://www.nasdaq.com/articles/ironwood-pharma-to-acquire-vectivbio-for-$1.15-bln
VectivBio Announces Pricing of Initial Public Offering
June 16, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2021/04/08/vectivbio-announces-pricing-of-initial-public-offering
What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story
February 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/recent-medicare-pricing-terms-mean-070520006.html
Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property
December 23, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/12/23/ironwood-settles-suit-vectivbio.html
Biotech acquired by Ironwood faces allegations of misappropriating trade secrets
November 11, 2025  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2025/11/11/ironwood-vectivbio-lawsuit.html
Ironwood’s shares sink as FDA demands new trial for lead drug
April 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/ironwood-s-shares-sink-as-fda-demands-new-trial-for-lead-drug/ar-AA1CYXei
A brain biotech launches with Roche’s spare parts
February 13, 2025  |  biopharmadive.comB
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
January 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aravax-continues-international-expansion-with-appointment-of-aled-williams-as-chief-business-officer-1034248130
CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer
December 5, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/cdr-life-appoints-sarah-holland-120000030.html
Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD
November 12, 2024  |  gut.bmj.comG
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight
September 23, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/graft-versus-host-disease-market-043000895.html
Etherio Group: 2024 CMI 25
September 21, 2024  |  meetingsnet.comM
Compare with VectivBio Holding AG (VECT)
May 29, 2024  |  msn.comhttps://www.msn.com/en-nz/money/compare?id=c1dbbh
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/engene-announces-election-paul-hastings-200500599.html
Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-05/62220612-vicore-pharma-holding-vicore-expands-and-strengthens-its-board-of-directors-200.htm
Vicore Expands and Strengthens its Board of Directors
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/vicore-expands-strengthens-board-directors-062000534.html
Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth
April 5, 2024  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/short-bowel-syndrome-market-2032-114900366.html
FDA approves DMD treatment from Italfarmaco
March 31, 2024  |  cen.acs.orgC
Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints
March 18, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/pipeline-moves-approval-prospects-for-sbs-candidate-rise-after-phase-iii-trial-meets-endpoints/ar-BB1k6DDg
IFLR Europe Awards 2024: shortlist revealed
February 8, 2024  |  iflr.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$3.47 -0.01 (-0.29%)
As of 09/4/2026 04:00 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

ProKidney stock logo

ProKidney NASDAQ:PROK

$2.01 +0.09 (+4.69%)
As of 09/4/2026 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

VectivBio stock logo

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)
As of 09/4/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas